140 related articles for article (PubMed ID: 33843423)
1. Co-delivery of CPP decorated doxorubicin and CPP decorated siRNA by NGR-modified nanobubbles for improving anticancer therapy.
Ma R; Nai J; Zhang J; Li Z; Xu F; Gao C
Pharm Dev Technol; 2021 Jul; 26(6):634-646. PubMed ID: 33843423
[TBL] [Abstract][Full Text] [Related]
2. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.
Lin W; Xie X; Deng J; Liu H; Chen Y; Fu X; Liu H; Yang Y
J Drug Target; 2016; 24(2):134-46. PubMed ID: 26176270
[TBL] [Abstract][Full Text] [Related]
3. Efficient siRNA Delivery Using Novel Cell-Penetrating Peptide-siRNA Conjugate-Loaded Nanobubbles and Ultrasound.
Xie X; Lin W; Li M; Yang Y; Deng J; Liu H; Chen Y; Fu X; Liu H; Yang Y
Ultrasound Med Biol; 2016 Jun; 42(6):1362-74. PubMed ID: 27012462
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
Chen Y; Wu JJ; Huang L
Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
[TBL] [Abstract][Full Text] [Related]
5. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
Yang Y; Yang Y; Xie X; Wang Z; Gong W; Zhang H; Li Y; Yu F; Li Z; Mei X
Biomaterials; 2015 Apr; 48():84-96. PubMed ID: 25701034
[TBL] [Abstract][Full Text] [Related]
6. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
7. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
8. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
9. Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery.
Xie X; Yang Y; Lin W; Liu H; Liu H; Yang Y; Chen Y; Fu X; Deng J
Colloids Surf B Biointerfaces; 2015 Dec; 136():641-50. PubMed ID: 26492155
[TBL] [Abstract][Full Text] [Related]
10. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
[TBL] [Abstract][Full Text] [Related]
12. Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy.
Yang H; Shen X; Yan J; Xie X; Chen Z; Li T; Li S; Qin X; Wu C; Liu Y
Biomater Sci; 2018 Aug; 6(9):2426-2439. PubMed ID: 30040100
[TBL] [Abstract][Full Text] [Related]
13. Dual stimulus of hyperthermia and intracellular redox environment triggered release of siRNA for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Xu X; Xia X; Wang H; Li L; Dong W; Ma P; Liu Y
Int J Pharm; 2016 Jun; 506(1-2):158-73. PubMed ID: 27106526
[TBL] [Abstract][Full Text] [Related]
14. Novel Class of Ultrasound-Triggerable Drug Delivery Systems for the Improved Treatment of Tumors.
Zhou C; Xie X; Yang H; Zhang S; Li Y; Kuang C; Fu S; Cui L; Liang M; Gao C; Yang Y; Gao C; Yang C
Mol Pharm; 2019 Jul; 16(7):2956-2965. PubMed ID: 31084010
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
16. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.
Mainelis G; Seshadri S; Garbuzenko OB; Han T; Wang Z; Minko T
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):345-54. PubMed ID: 23530772
[TBL] [Abstract][Full Text] [Related]
17. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
18. Deepened cellular/subcellular interface penetration and enhanced antitumor efficacy of cyclic peptidic ligand-decorated accelerating active targeted nanomedicines.
Shi NQ; Li Y; Zhang Y; Li ZQ; Qi XR
Int J Nanomedicine; 2018; 13():5537-5559. PubMed ID: 30271146
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
[TBL] [Abstract][Full Text] [Related]
20. Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2.
Xiang Y; Shan W; Huang Y
Int J Pharm; 2018 Nov; 551(1-2):14-22. PubMed ID: 30205127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
